Search Results - charles+drake

6 Results

Sort By:

Neuritin Impact T Cell Tolerance Induction and Maintenance and is a Target for Tumor Immunotherapy

Unmet NeedCancer immunotherapy is a therapeutic approach that has revolutionized advanced cancer treatment. In particular, the use of therapeutic blocking antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein (PD-1) has achieved routine clinical use in numerous indications. Despite these promising results, monotherapy...

Published: 3/14/2025 | Inventor(s): Drew Pardoll, Hong Yu, Joseph Barbi, Fan Pan, Charles Drake

Keywords(s): Antibodies, Autoimmune Diseases, Biologics, Cancers, Combination, Disease Indication, Inflammatory Disorders, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists

Unmet NeedThe recent breakthroughs in immuno-oncology have changed the way that researchers think about treating autoimmune diseases and cancer by modulating the immune system. Regulatory T cells (Treg) limit autoimmunity but also attenuate the potency of antitumor immunity. Enhancement of Treg function could treat autoimmune diseases while the inhibition...

Published: 3/13/2025 | Inventor(s): Drew Pardoll, Joseph Barbi, Fan Pan, Hong Yu, Ching-Tai Huang, Xiaoyu Pan, Charles Drake, Jonathan Powell

Keywords(s): Antibodies, Biologics, Cancers, Disease Indication, Immunotherapy, Infectious Diseases, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics

Mouse Anti-LAG3 Monoclonal Antibody (4-10-C9)

C11691: Mouse LAG-3 Monoclonal AntibodyNovelty: A mouse monoclonal antibody (mAb) against LAG-3 (Lymphocyte Activation Gene 3).Value Proposition: LAG-3 is expressed on the cell surface of activated T-cells and is known to be an important global regulatory molecule that controls many aspects of T-cell proliferation and homeostasis. This invention is...

Published: 3/13/2025 | Inventor(s): Dario Vignali, Charles Drake

Keywords(s): Antibodies, Basic Research Biomarker, Discovery/Research Tools, Monoclonal Antibodies, Proteomics/Immunoassays, Proteomics/Immunoassays Antibodies, Research Reagent

Category(s): Technology Classifications > Research Tools > Antibodies, Technology Classifications > Research Tools > Assays, Technology Classifications > Research Tools

C11601: Novel Adjuvant Based Approach to Enhance Cancer Immunotherapy

Novelty: This invention is a novel means of augmenting immune-based cancer therapies by using a physical intervention to counter a tumor's natural immunosuppressive effect.Value Proposition: This therapeutic strategy combines two accepted approaches to cancer management - immune-based and physical - for an increase in survival that is durable and significantly...

Published: 3/13/2025 | Inventor(s): Charles Drake, Drew Pardoll, Jing Zeng, Michael Lim

Keywords(s): Cancers, Combination, Disease Indication, External Beam Radiation, Immunotherapy/Radiation therapy, Interventional and Surgical Systems, Surgical Intervention Method, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Medical Devices, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Manipulation of the Transcription Factor Helios to Enhance or Down-modulate Regulatory T Cell Function

C10323: Modulation of Regulatory T cell (Treg) Function Value Proposition: • Up-regulate immune response • Down-regulate immune response • Treatment of cancer, infection, autoimmunity, and inflammationTechnical Details: Regulatory T cells (Treg) are a subset of the CD4 T cell population that down-modulate an immune response. In some diseases, i.e....

Published: 3/13/2025 | Inventor(s): Jonathan Powell, Joseph Grosso, Edward Hipkiss, Drew Pardoll, Derese Getnet, Charles Drake

Keywords(s): Autoimmune Diseases, Biomarker, Cancers, Disease Indication, Inflammatory Disorders, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Inflammation, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Inducing and Inhibiting T Cell Tolerance with A2a Receptor Agonists and Antagonists

C04897: Inducing and Inhibiting T Cell Tolerance with A2a Receptor Agonists and AntagonistsValue Proposition: • Therapeutic target for developing tolerance-inducing agents and tolerance-inhibiting agents for the treatment of autoimmune disease and cancer • Methods of treating an infection by enhancing the generation of antigen-specific...

Published: 3/13/2025 | Inventor(s): Paul Zarek, Charles Drake, Jonathan Powell

Keywords(s): Agonists/Promoters, Antagonists/Inhibitors, Autoimmune Diseases, Cancers, Disease Indication, Immunotherapy, Infectious Diseases, Inflammatory Disorders, Non-novel, Predicted Novelty, Repurposed, Single, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Inflammation, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities